Evaluating FAP expression before immunotherapy in mesothelioma patients
Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
This study is testing if a special imaging technique can help predict how well immunotherapy will work for people with pleural mesothelioma before they start treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ankara University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Ankara) |
| Trial ID | NCT06451536 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the expression of fibroblast activation protein (FAP) using Ga-68 FAPI PET/CT imaging in patients diagnosed with pleural mesothelioma who are scheduled to receive immunotherapy. Patients will undergo imaging within 10 days prior to starting treatment, allowing researchers to gather data on various parameters such as SUVmax, SUVmean, and metabolic tumor volume. The study will then analyze the correlation between these imaging findings and the patients' responses to immunotherapy, potentially providing insights into treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a histopathologically confirmed diagnosis of pleural mesothelioma who are scheduled to receive immunotherapy.
Not a fit: Patients with an ECOG performance status greater than 2 or those who do not provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict treatment responses in mesothelioma patients, leading to more personalized and effective immunotherapy strategies.
How similar studies have performed: While the use of Ga-68 FAPI PET/CT imaging in this context is relatively novel, similar studies have shown promise in evaluating treatment responses in other cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having a histopathologically confirmed diagnosis of * Pleural Mesolthelioma * Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy * Patients who gave informed consent form to participate in the study Exclusion Criteria: * ECOG\>2 * Patients who did not provide informed consent form to participate in the study
Where this trial is running
Ankara
- Ankara University School of Medicine — Ankara, Turkey (Türkiye) (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.